Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Immunity ; 56(6): 1320-1340.e10, 2023 06 13.
Article in English | MEDLINE | ID: mdl-37315535

ABSTRACT

CD8+ T cell exhaustion (Tex) limits disease control during chronic viral infections and cancer. Here, we investigated the epigenetic factors mediating major chromatin-remodeling events in Tex-cell development. A protein-domain-focused in vivo CRISPR screen identified distinct functions for two versions of the SWI/SNF chromatin-remodeling complex in Tex-cell differentiation. Depletion of the canonical SWI/SNF form, BAF, impaired initial CD8+ T cell responses in acute and chronic infection. In contrast, disruption of PBAF enhanced Tex-cell proliferation and survival. Mechanistically, PBAF regulated the epigenetic and transcriptional transition from TCF-1+ progenitor Tex cells to more differentiated TCF-1- Tex subsets. Whereas PBAF acted to preserve Tex progenitor biology, BAF was required to generate effector-like Tex cells, suggesting that the balance of these factors coordinates Tex-cell subset differentiation. Targeting PBAF improved tumor control both alone and in combination with anti-PD-L1 immunotherapy. Thus, PBAF may present a therapeutic target in cancer immunotherapy.


Subject(s)
CD8-Positive T-Lymphocytes , Chromatin Assembly and Disassembly , Chromatin , Cell Differentiation , Epigenesis, Genetic
2.
EMBO J ; 42(9): e111494, 2023 05 02.
Article in English | MEDLINE | ID: mdl-36919984

ABSTRACT

Tumor growth is influenced by a complex network of interactions between multiple cell types in the tumor microenvironment (TME). These constrained conditions trigger the endoplasmic reticulum (ER) stress response, which extensively reprograms mRNA translation. When uncontrolled over time, chronic ER stress impairs the antitumor effector function of CD8 T lymphocytes. How cells promote adaptation to chronic stress in the TME without the detrimental effects of the terminal unfolded protein response (UPR) is unknown. Here, we find that, in effector CD8 T lymphocytes, RNA-binding protein CPEB4 constitutes a new branch of the UPR that allows cells to adapt to sustained ER stress, yet remains decoupled from the terminal UPR. ER stress, induced during CD8 T-cell activation and effector function, triggers CPEB4 expression. CPEB4 then mediates chronic stress adaptation to maintain cellular fitness, allowing effector molecule production and cytotoxic activity. Accordingly, this branch of the UPR is required for the antitumor effector function of T lymphocytes, and its disruption in these cells exacerbates tumor growth.


Subject(s)
Endoplasmic Reticulum Stress , Neoplasms , Humans , Endoplasmic Reticulum Stress/genetics , Unfolded Protein Response , Neoplasms/metabolism , CD8-Positive T-Lymphocytes/metabolism , Adaptation, Physiological , Tumor Microenvironment , RNA-Binding Proteins/metabolism
3.
Genome Med ; 13(1): 168, 2021 10 26.
Article in English | MEDLINE | ID: mdl-34702310

ABSTRACT

BACKGROUND: In spite of many years of research, our understanding of the molecular bases of Alzheimer's disease (AD) is still incomplete, and the medical treatments available mainly target the disease symptoms and are hardly effective. Indeed, the modulation of a single target (e.g., ß-secretase) has proven to be insufficient to significantly alter the physiopathology of the disease, and we should therefore move from gene-centric to systemic therapeutic strategies, where AD-related changes are modulated globally. METHODS: Here we present the complete characterization of three murine models of AD at different stages of the disease (i.e., onset, progression and advanced). We combined the cognitive assessment of these mice with histological analyses and full transcriptional and protein quantification profiling of the hippocampus. Additionally, we derived specific Aß-related molecular AD signatures and looked for drugs able to globally revert them. RESULTS: We found that AD models show accelerated aging and that factors specifically associated with Aß pathology are involved. We discovered a few proteins whose abundance increases with AD progression, while the corresponding transcript levels remain stable, and showed that at least two of them (i.e., lfit3 and Syt11) co-localize with Aß plaques in the brain. Finally, we found two NSAIDs (dexketoprofen and etodolac) and two anti-hypertensives (penbutolol and bendroflumethiazide) that overturn the cognitive impairment in AD mice while reducing Aß plaques in the hippocampus and partially restoring the physiological levels of AD signature genes to wild-type levels. CONCLUSIONS: The characterization of three AD mouse models at different disease stages provides an unprecedented view of AD pathology and how this differs from physiological aging. Moreover, our computational strategy to chemically revert AD signatures has shown that NSAID and anti-hypertensive drugs may still have an opportunity as anti-AD agents, challenging previous reports.


Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Proteomics/methods , Transcriptome , Aging , Amyloid beta-Peptides , Animals , Brain/metabolism , Cognitive Dysfunction , Disease Models, Animal , Drug Discovery , Female , Gene Expression Regulation, Neoplastic , Gene Knock-In Techniques , Humans , Mice , Mice, Inbred C57BL , Mice, Transgenic , Plaque, Amyloid/metabolism
4.
Nat Commun ; 12(1): 3932, 2021 06 24.
Article in English | MEDLINE | ID: mdl-34168145

ABSTRACT

Chemical descriptors encode the physicochemical and structural properties of small molecules, and they are at the core of chemoinformatics. The broad release of bioactivity data has prompted enriched representations of compounds, reaching beyond chemical structures and capturing their known biological properties. Unfortunately, bioactivity descriptors are not available for most small molecules, which limits their applicability to a few thousand well characterized compounds. Here we present a collection of deep neural networks able to infer bioactivity signatures for any compound of interest, even when little or no experimental information is available for them. Our signaturizers relate to bioactivities of 25 different types (including target profiles, cellular response and clinical outcomes) and can be used as drop-in replacements for chemical descriptors in day-to-day chemoinformatics tasks. Indeed, we illustrate how inferred bioactivity signatures are useful to navigate the chemical space in a biologically relevant manner, unveiling higher-order organization in natural product collections, and to enrich mostly uncharacterized chemical libraries for activity against the drug-orphan target Snail1. Moreover, we implement a battery of signature-activity relationship (SigAR) models and show a substantial improvement in performance, with respect to chemistry-based classifiers, across a series of biophysics and physiology activity prediction benchmarks.


Subject(s)
Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Structure-Activity Relationship , Cell Line, Tumor , Databases, Pharmaceutical , Drug Evaluation, Preclinical/methods , Humans , Snail Family Transcription Factors/antagonists & inhibitors , Snail Family Transcription Factors/genetics , Snail Family Transcription Factors/metabolism
5.
J Chem Inf Model ; 60(12): 5730-5734, 2020 12 28.
Article in English | MEDLINE | ID: mdl-32672454

ABSTRACT

Until a vaccine becomes available, the current repertoire of drugs is our only therapeutic asset to fight the SARS-CoV-2 outbreak. Indeed, emergency clinical trials have been launched to assess the effectiveness of many marketed drugs, tackling the decrease of viral load through several mechanisms. Here, we present an online resource, based on small-molecule bioactivity signatures and natural language processing, to expand the portfolio of compounds with potential to treat COVID-19. By comparing the set of drugs reported to be potentially active against SARS-CoV-2 to a universe of 1 million bioactive molecules, we identify compounds that display analogous chemical and functional features to the current COVID-19 candidates. Searches can be filtered by level of evidence and mechanism of action, and results can be restricted to drug molecules or include the much broader space of bioactive compounds. Moreover, we allow users to contribute COVID-19 drug candidates, which are automatically incorporated to the pipeline once per day. The computational platform, as well as the source code, is available at https://sbnb.irbbarcelona.org/covid19.


Subject(s)
Antiviral Agents/chemistry , COVID-19 Drug Treatment , Drug Repositioning/methods , SARS-CoV-2/drug effects , Antiviral Agents/pharmacology , Computer Simulation , Drug Design , Humans , Models, Molecular , Molecular Structure , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology
6.
Nat Biotechnol ; 38(9): 1098, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32440008

ABSTRACT

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

7.
Nat Biotechnol ; 38(9): 1087-1096, 2020 09.
Article in English | MEDLINE | ID: mdl-32440005

ABSTRACT

Small molecules are usually compared by their chemical structure, but there is no unified analytic framework for representing and comparing their biological activity. We present the Chemical Checker (CC), which provides processed, harmonized and integrated bioactivity data on ~800,000 small molecules. The CC divides data into five levels of increasing complexity, from the chemical properties of compounds to their clinical outcomes. In between, it includes targets, off-targets, networks and cell-level information, such as omics data, growth inhibition and morphology. Bioactivity data are expressed in a vector format, extending the concept of chemical similarity to similarity between bioactivity signatures. We show how CC signatures can aid drug discovery tasks, including target identification and library characterization. We also demonstrate the discovery of compounds that reverse and mimic biological signatures of disease models and genetic perturbations in cases that could not be addressed using chemical information alone. Overall, the CC signatures facilitate the conversion of bioactivity data to a format that is readily amenable to machine learning methods.


Subject(s)
Pharmaceutical Preparations/metabolism , Small Molecule Libraries/metabolism , Biological Products/chemistry , Biological Products/metabolism , Biological Products/therapeutic use , Biomarkers, Pharmacological/metabolism , Databases, Factual , Drug Discovery , Drug Therapy , Humans , Pharmaceutical Preparations/chemistry , Small Molecule Libraries/chemistry , Small Molecule Libraries/therapeutic use
8.
West J Emerg Med ; 18(6): 1120-1127, 2017 Oct.
Article in English | MEDLINE | ID: mdl-29085546

ABSTRACT

INTRODUCTION: Emergency medicine (EM) is in different stages of development around the world. Colombia has made significant strides in EM development in the last two decades and recognized it as a medical specialty in 2005. The country now has seven EM residency programs: three in the capital city of Bogotá, two in Medellin, one in Manizales, and one in Cali. The seven residency programs are in different stages of maturity, with the oldest founded 20 years ago and two founded in the last two years. The objective of this study was to characterize these seven residency programs. METHODS: We conducted semi-structured interviews with faculty and residents from all the existing programs in 2013-2016. Topics included program characteristics and curricula. RESULTS: Colombian EM residencies are three-year programs, with the exception of one four-year program. Programs accept 3-10 applicants yearly. Only one program has free tuition and the rest charge tuition. The number of EM faculty ranges from 2-15. EM rotation requirements range from 11-33% of total clinical time. One program does not have a pediatric rotation. The other programs require 1-2 months of pediatrics or pediatric EM. Critical care requirements range from 4-7 months. Other common rotations include anesthesia, general surgery, internal medicine, obstetrics, gynecology, orthopedics, ophthalmology, radiology, toxicology, psychiatry, neurology, cardiology, pulmonology, and trauma. All programs offer 4-6 hours of protected didactic time each week. Some programs require Advanced Cardiac Life Support, Pediatric Advanced Life Support and Advanced Trauma Life Support, with some programs providing these trainings in-house or subsidizing the cost. Most programs require one research project for graduation. Resident evaluations consist of written tests and oral exams several times per year. Point-of-care ultrasound training is provided in four of the seven programs. CONCLUSION: As emergency medicine continues to develop in Colombia, more residency programs are expected to emerge. Faculty development and sustainability of academic pursuits will be critically important. In the long term, the specialty will need to move toward certifying board exams and professional development through a national EM organization to promote standardization across programs.


Subject(s)
Education, Medical, Graduate/standards , Emergency Medicine/education , Internship and Residency/standards , Program Development/standards , Colombia , Curriculum , Emergency Medicine/standards , Humans , Program Evaluation
9.
Cancer Res ; 77(2): 459-469, 2017 01 15.
Article in English | MEDLINE | ID: mdl-27879272

ABSTRACT

Combinatorial therapeutic approaches are an imperative to improve cancer treatment, because it is critical to impede compensatory signaling mechanisms that can engender drug resistance to individual targeted drugs. Currently approved drug combinations result largely from empirical clinical experience and cover only a small fraction of a vast therapeutic space. Here we present a computational network biology approach, based on pathway cross-talk inhibition, to discover new synergistic drug combinations for breast cancer treatment. In silico analysis identified 390 novel anticancer drug pairs belonging to 10 drug classes that are likely to diminish pathway cross-talk and display synergistic antitumor effects. Ten novel drug combinations were validated experimentally, and seven of these exhibited synergy in human breast cancer cell lines. In particular, we found that one novel combination, pairing the estrogen response modifier raloxifene with the c-Met/VEGFR2 kinase inhibitor cabozantinib, dramatically potentiated the drugs' individual antitumor effects in a mouse model of breast cancer. When compared with high-throughput combinatorial studies without computational prioritization, our approach offers a significant advance capable of uncovering broad-spectrum utility across many cancer types. Cancer Res; 77(2); 459-69. ©2016 AACR.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Breast Neoplasms/metabolism , Computational Biology/methods , Drug Synergism , Receptor Cross-Talk/drug effects , Animals , Cell Survival/drug effects , Female , High-Throughput Screening Assays , Humans , Mice , Xenograft Model Antitumor Assays
10.
J Mol Biol ; 427(6 Pt B): 1436-1450, 2015 Mar 27.
Article in English | MEDLINE | ID: mdl-25640309

ABSTRACT

Despite the remarkable progress achieved in the identification of specific genes involved in breast cancer (BC), our understanding of their complex functioning is still limited. In this manuscript, we systematically explore the existence of direct physical interactions between the products of BC core and associated genes. Our aim is to generate a protein interaction network of BC-associated gene products and suggest potential molecular mechanisms to unveil their role in the disease. In total, we report 599 novel high-confidence interactions among 44 BC core, 54 BC candidate/associated and 96 newly identified proteins. Our findings indicate that this network-based approach is indeed a robust inference tool to pinpoint new potential players and gain insight into the underlying mechanisms of those proteins with previously unknown roles in BC. To illustrate the power of our approach, we provide initial validation of two BC-associated proteins on the alteration of DNA damage response as a result of specific re-wiring interactions. Overall, our BC-related network may serve as a framework to integrate clinical and molecular data and foster novel global therapeutic strategies.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Computational Biology/methods , Gene Regulatory Networks , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Protein Interaction Maps , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cells, Cultured , DNA Damage/genetics , Female , Fluorescent Antibody Technique , Genetic Predisposition to Disease , Humans , Immunoprecipitation , Oligonucleotide Array Sequence Analysis , Two-Hybrid System Techniques
12.
PLoS One ; 10(1): e0115352, 2015.
Article in English | MEDLINE | ID: mdl-25590583

ABSTRACT

A key element to delineate the biology of individual tumors is the regulation of apoptosis. In this work, we functionally characterize two breast cancer associated genes, the proteasome 26S subunit ATPase 3 interacting protein (PSMC3IP) and the epithelial-stromal interaction 1 (EPSTI1), to explore their potential apoptotic role in breast cancer. We first explore the existence of direct physical interactions with annotated BC-apoptotic genes. Based on the generated interaction network, we examine several apoptotic markers to determine the effect of PSMC3IP and EPSTI1 gene expression modulation in two different human breast cancer cell lines to suggest potential molecular mechanisms to unveil their role in the disease. Our results show that PSMC3IP and EPSTI1 are able to modulate the extrinsic apoptotic pathway in estrogen receptor positive and triple negative breast cancer cell lines, highlighting them as potential therapeutic targets.


Subject(s)
Apoptosis/genetics , Breast Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Neoplasm Proteins/genetics , Nuclear Proteins/genetics , Trans-Activators/genetics , Breast Neoplasms/pathology , Cell Line, Tumor , Female , Humans
13.
Rev. esp. cardiol. (Ed. impr.) ; 67(6): 449-455, jun. 2014. mapas
Article in Spanish | IBECS | ID: ibc-123218

ABSTRACT

INTRODUCCIÓN Y OBJETIVO:S: Analizar la asociación entre tiempo sentado y biomarcadores de resistencia a la insulina e inflamación en una población de trabajadores varones. MÉTODOS: Estudio transversal realizado sobre 929 voluntarios, pertenecientes a la cohorte del Aragon Workers' Health Study. Se obtuvieron datos sociodemográficos, antropométricos, farmacológicos y bioquímicos: lipídicos -colesterol total, colesterol unido a lipoproteínas de alta y baja densidad, triglicéridos, apolipoproteínas A1 y B100 y lipoproteína (a)-, glucídicos -glucosa, glucohemoglobina, homeostasis model assessment of insulin resistance, insulina y cociente triglicéridos/colesterol unido a lipoproteínas de alta densidad- e inflamatorios -proteína C reactiva y leucocitos-. El tiempo sentado y la actividad física realizada se obtuvieron mediante cuestionarios. Se realizó un análisis de prevalencias y medianas según terciles de sedentarismo y multivariable (regresión lineal bruta y ajustada) con los biomarcadores de inflamación y de resistencia a la insulina. RESULTADOS: Los trabajadores más sedentarios presentan unas medianas de índice de masa corporal, perímetro de cintura y presión arterial sistólica mayores, con una tendencia significativa de aumento en cada tercil, peor perfil lipídico, valores más elevados de proteína C reactiva, homeostasis model assessment of insulin resistance, cociente triglicéridos/colesterol unido a lipoproteínas de alta densidad e insulina. En el modelo de regresión lineal bruta y ajustada, encontramos una asociación significativa de estas últimas variables con el tiempo de posición de sentado medido en horas (β = 0,07 [log proteína C reactiva]; β = 0,05 [log homeostasis model assessment of insulin resistance]; β = 0,23 [triglicéridos/colesterol unido a lipoproteínas de alta densidad], y β = 0,44 [insulina]) que no se modifican tras ajustar por los equivalentes metabólicos-h/semana. CONCLUSIONES: Los trabajadores más sedentarios presentan parámetros inflamatorios y de resistencia a la insulina más altos de manera independiente de la actividad física realizada


INTRODUCTION AND OBJECTIVES: To analyze the association between sitting time and biomarkers of insulin resistance and inflammation in a sample of healthy male workers. Methods Cross-sectional study carried out in a sample of 929 volunteers belonging to the Aragon Workers' Health Study cohort. Sociodemographic, anthropometric, pharmacological and laboratory data were collected: lipids-total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, apolipoproteins A-1 and B-100, lipoprotein (a)-, insulin resistance-glucose, glycated hemoglobin, homeostasis model assessment of insulin resistance, insulin, and triglyceride/high-density lipoprotein cholesterol ratio-, and inflammatory profile-C-reactive protein and leukocytes. Information on sitting time and physical activity was assessed using a questionnaire. Sedentary behavior was analyzed in terms of prevalences and medians, according to tertiles, using a multivariate model


Subject(s)
Humans , Male , Inflammation/epidemiology , Metabolic Syndrome/epidemiology , Cardiovascular Diseases/epidemiology , Sedentary Behavior , Inflammation Mediators/analysis , Insulin Resistance , Risk Factors , Biomarkers/analysis
14.
Rev Esp Cardiol (Engl Ed) ; 67(6): 449-55, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24863593

ABSTRACT

INTRODUCTION AND OBJECTIVES: To analyze the association between sitting time and biomarkers of insulin resistance and inflammation in a sample of healthy male workers. METHODS: Cross-sectional study carried out in a sample of 929 volunteers belonging to the Aragon Workers' Health Study cohort. Sociodemographic, anthropometric, pharmacological and laboratory data were collected: lipids-total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, apolipoproteins A-1 and B-100, lipoprotein (a)-, insulin resistance-glucose, glycated hemoglobin, homeostasis model assessment of insulin resistance, insulin, and triglyceride/high-density lipoprotein cholesterol ratio-, and inflammatory profile-C-reactive protein and leukocytes. Information on sitting time and physical activity was assessed using a questionnaire. Sedentary behavior was analyzed in terms of prevalences and medians, according to tertiles, using a multivariate model (crude and adjusted linear regression) with biomarkers of inflammation and insulin resistance. RESULTS: The most sedentary individuals had higher body mass index, greater waist circumference, and higher systolic blood pressure, with a significant upward trend in each tertile. Likewise, they had a worse lipid profile with a higher C-reactive protein level, homeostasis model assessment of insulin resistance index, triglyceride/high-density lipoprotein cholesterol ratio, and insulin concentration. In the multivariate analysis, we observed a significant association between the latter parameters and sitting time in hours (log C-reactive protein [ß = 0.07], log homeostasis model assessment of insulin resistance index [ß = 0.05], triglyceride/high-density lipoprotein cholesterol ratio [ß = 0.23], and insulin [ß = 0.44]), which remained after adjustment for metabolic equivalents-h/week. CONCLUSIONS: Workers who spend more time sitting show a worse inflammatory and insulin resistance profile independently of the physical activity performed.


Subject(s)
Cardiovascular Diseases/epidemiology , Inflammation/epidemiology , Insulin Resistance , Sedentary Behavior , Cross-Sectional Studies , Humans , Male , Middle Aged , Prospective Studies , Risk Factors
16.
Med. clín (Ed. impr.) ; 140(11): 487-492, jun. 2013. tab, ilus
Article in Spanish | IBECS | ID: ibc-112473

ABSTRACT

Fundamento y objetivo: La hipertensión arterial es el factor de riesgo más prevalente. Nuestro objetivo fue describir los factores asociados a la progresión de la presión arterial (PA) desde valores normales. Sujetos y método: Estudio prospectivo y observacional con 7 años de seguimiento. Se consideró hipertensión valores de PA≥140/90mmHg. Se elaboró un modelo multivariante para identificar los factores asociados a la progresión de la PA y una escala de predicción. Resultados: Los 2.236 varones, con una mediana de edad de 42 años, presentaron características diferenciales en función de su categoría de PA basal. Al final de los 7 años de seguimiento, el 31.,9% de los sujetos normotensos al inicio del estudio presentaron un incremento de la PA como para ser diagnosticados de hipertensión arterial. Los sujetos basalmente normotensos que presentaron progresión de PA partían de valores más cercanos al límite de la normalidad y un perfil lipídico más desfavorable. Se elaboró una escala que incluyó las siguientes variables: edad, antecedentes familiares de hipertensión, categorías de índice de masa corporal, glucosa>100mg/dl, triglicéridos>150mg/dl y ácido úrico. La puntuación total obtenible tiene que estar entre -2 y 24 y se calculó para cada uno de los valores el riesgo de progresión. Conclusiones: La progresión de la PA desde la normotensión a la hipertensión en los siguientes 7 años en varones jóvenes es alta y se puede estimar con una simple escala de riesgo (AU)


Background and objective: Hypertension is the most prevalent risk factor in the community. The aim of this study was to describe the risk factors for the progression of blood pressure (BP) from correct values. Subjects and methods: Prospective and observational study with 7 years follow-up. BP > 140/90 mmHg was considered hypertension. A multivariate model was performed to assess risk factors for BP progression and a predictive score. Results: The 2,236 males, median age 42 years, had differential characteristics according to their baseline BP category. At the end of the 7-years follow-up 31.9% of baseline-normotensive subjects had an increase of their BP to the range of hypertension. Baseline-normotensive subjects who experienced a progression of BP had higher baseline BP and less favourable lipid profile. A risk score was performed using the following variables: age, hypertension familiar history, overweight and obesity, glucose > 100 mg/dl, triglycerides > 150 mg/dl and uric acid. Total score ranged between -2 and 24; the risk of BP progression beyond normal thresholds increased linearly as the score increased. Conclusions: Progression of BP from normotension to higher BP categories into the next 7 years in young males and the risk can be estimated by a simple score (AU)


Subject(s)
Humans , Male , Blood Pressure Determination , Hypertension/epidemiology , Risk Adjustment/methods , Disease Progression , Risk Factors , Prognosis
17.
PLoS One ; 8(3): e58837, 2013.
Article in English | MEDLINE | ID: mdl-23520537

ABSTRACT

A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-ß (Aß) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by ß- and γ-secretases. Based on a systems biology study to repurpose drugs for AD, we explore the effect of lansoprazole, and other proton-pump inhibitors (PPIs), on Aß production in AD cellular and animal models. We found that lansoprazole enhances Aß37, Aß40 and Aß42 production and lowers Aß38 levels on amyloid cell models. Interestingly, acute lansoprazole treatment in wild type and AD transgenic mice promoted higher Aß40 levels in brain, indicating that lansoprazole may also exacerbate Aß production in vivo. Overall, our data presents for the first time that PPIs can affect amyloid metabolism, both in vitro and in vivo.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/pharmacology , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/biosynthesis , Enzyme Inhibitors/pharmacology , Proton Pump Inhibitors , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/genetics , Animals , CHO Cells , Cricetinae , Cricetulus , Disease Models, Animal , Female , Humans , Lansoprazole , Mice , Mice, Knockout
18.
Med Clin (Barc) ; 140(11): 487-92, 2013 Jun 04.
Article in Spanish | MEDLINE | ID: mdl-23199830

ABSTRACT

BACKGROUND AND OBJECTIVE: Hypertension is the most prevalent risk factor in the community. The aim of this study was to describe the risk factors for the progression of blood pressure (BP) from correct values. SUBJECTS AND METHODS: Prospective and observational study with 7 years follow-up. BP>140/90 mmHg was considered hypertension. A multivariate model was performed to assess risk factors for BP progression and a predictive score. RESULTS: The 2,236 males, median age 42 years, had differential characteristics according to their baseline BP category. At the end of the 7-years follow-up 31.9% of baseline-normotensive subjects had an increase of their BP to the range of hypertension. Baseline-normotensive subjects who experienced a progression of BP had higher baseline BP and less favourable lipid profile. A risk score was performed using the following variables: age, hypertension familiar history, overweight and obesity, glucose>100mg/dl, triglycerides>150 mg/dl and uric acid. Total score ranged between -2 and 24; the risk of BP progression beyond normal thresholds increased linearly as the score increased. CONCLUSIONS: Progression of BP from normotension to higher BP categories into the next 7 years in young males and the risk can be estimated by a simple score.


Subject(s)
Hypertension/epidemiology , Surveys and Questionnaires , Adult , Blood Pressure , Body Mass Index , Comorbidity , Disease Progression , Dyslipidemias/epidemiology , Employment , Follow-Up Studies , Humans , Hyperglycemia/epidemiology , Hypertension/diagnosis , Hypertriglyceridemia/epidemiology , Hyperuricemia/epidemiology , Lipoproteins, LDL/blood , Male , Middle Aged , Models, Biological , Multivariate Analysis , Obesity/epidemiology , Physical Examination , Prospective Studies , Risk Assessment , Risk Factors , Spain/epidemiology
20.
Immunity ; 31(1): 145-57, 2009 Jul 17.
Article in English | MEDLINE | ID: mdl-19604493

ABSTRACT

Although deficient CD8(+) T cell responses have long been associated with chronic viral infections, the underlying mechanisms are still unclear. Here we report that sustained transforming growth factor-beta (TGF-beta) expression and phosphorylation of its signaling mediator, Smad-2, were distinctive features of virus-specific CD8(+) T cells during chronic versus acute viral infections in vivo. The result was TGF-beta-dependent apoptosis of virus-specific CD8(+) T cells that related to upregulation of the proapoptotic protein Bim during chronic infection. Moreover, selective attenuation of TGF-beta signaling in T cells increased the numbers and multiple functions of antiviral CD8(+) T cells and enabled rapid eradication of the persistence-prone virus and memory generation. Finally, we found that cell-intrinsic TGF-beta signaling was responsible for virus-specific-CD8(+) T cell apoptosis and decreased numbers but was not necessary for their functional exhaustion. Our findings reveal persisting TGF-beta-Smad signaling as a hallmark and key regulator of CD8(+) T cell responses during chronic viral infections in vivo.


Subject(s)
Apoptosis Regulatory Proteins/immunology , Arenaviridae Infections/immunology , CD8-Positive T-Lymphocytes/immunology , Membrane Proteins/immunology , Proto-Oncogene Proteins/immunology , Smad2 Protein/immunology , Transforming Growth Factor beta/immunology , Adoptive Transfer , Animals , Apoptosis/immunology , Apoptosis Regulatory Proteins/metabolism , Arenaviridae Infections/virology , Bcl-2-Like Protein 11 , CD8-Positive T-Lymphocytes/metabolism , Lymphocyte Depletion , Lymphocytic choriomeningitis virus/immunology , Membrane Proteins/metabolism , Mice , Mice, Inbred C57BL , Phosphorylation/immunology , Proto-Oncogene Proteins/metabolism , Signal Transduction/immunology , Smad2 Protein/metabolism , Transforming Growth Factor beta/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...